13 May 2019
Yokohama Japan, 13 May 2019: REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders. The suite has been designed to support Clinical Trials of cell therapy products.
REPROCELL has been jointly developing iGRP with Q Therapeutics Inc. (Utah, USA) for treatment of various intractable CNS diseases and injuries. The target indications of iGRP include Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) Transverse Myelitis (TM), Spinal Cord Injuries (SCI) and Stroke. REPROCELL will manufacture clinical grade iGRP at the suite to conduct preclinical safety/efficacy studies and clinical trial.
In addition, REPROCELL plans to manufacture and store clinical grade iPS Cell Bank as raw material for iPS Cell-derived cellular products at the suite according to US/EU/Japan regulations and guidelines, and plans to support academia and industry for manufacturing materials for animal studies and clinical trials.
Life Innovation Center (LIC) in Kanagawa was launched in April 2016 for the industrialization of regenerative medicine and cell therapy. The center is located at Tonomachi area in Kawasaki city, where cutting-edge companies and institutions in the life science field cluster. Led by Kanagawa, the Center works closely with the national government and academia and industry, utilizing merits of National Strategic Special Zones.
Life Innovation Center (Photo by Kanagawa prefecture)
Q Therapeutics is a privately-held U.S. biotechnology company founded on the ground-breaking work of Dr. Mahendra Rao during his tenure at the University of Utah and the National Institutes of Health. Dr. Rao is recognized as one of the world’s top stem cell researchers, particularly in the area of neural stem cells and, until recently, served as the Director of the Intramural Center for Regenerative Medicine at the National Institutes of Health (NIH).
REPROCELL was established in 2003 with a goal of contributing to people’s health and welfare through the development of stem cell technologies. REPROCELL successfully went public in 2013 as the first iPS cell company on JASDAQ, Tokyo Stock Exchange Market, and then started to expand their business to global rapidly through several M&As. REPROCELL are pursuing two business areas of Discovery and Medical using proprietary human cell technologies including stem cells, biorepository, bioengineered tissue and drug screening.
Please contact email@example.com for more information.